Atomoxetine and Stimulant Medications in Children and Adolescents with Persistent Symptoms of Attention Deficit Hyperactivity Disorder despite Monotherapy
Abstract:A 10-year-old, 30-kg boy with attention deficit hyperactivity disorder (ADHD) is taking osmoticrelease oral system methylphenidate (Concerta) 36 mg once daily in the morning. Because his ADHD symptoms are only partially controlled with this monotherapy, several attempts have been made to increase the dose. However, each increase has resulted in intolerable gastrointestinal adverse effects. Today, his mother has dropped off a new prescription for atomoxetine 18 mg once daily for 2 weeks, to be followed by 25 mg… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.